Clinical trials
Idiopathic Pulmonary Fibrosis clinical trials
Below are recruiting idiopathic pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 86 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00373841Recruiting
Study of genetic and protein changes in idiopathic pulmonary fibrosis
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT00258570Recruiting
Study genetics in idiopathic pulmonary fibrosis patients
This study looks at genetic differences in people with idiopathic pulmonary fibrosis (a lung scarring condition with no known cause). It may help researchers understand what influences the disease and guide future treatment options.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06488638Recruiting
Beetroot juice supplement for lung fibrosis
This trial tests whether a beetroot juice drink (rich in nitrates) can help people with idiopathic pulmonary fibrosis breathe better and exercise more. It's a small pilot study to see if it's safe and worth studying further.
SouthamptonAges 18–85 - NCT07447102RecruitingPhase 2
Study of BC006 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT07464912RecruitingPhase 3
Testing TDI01 for idiopathic pulmonary fibrosis
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Beijing, Beijing MunicipalityAges 40–80 - NCT07466420Recruiting
Quercetin for fibrotic lung disease
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
Heraklion, CreteAges 18 years+ - NCT07486206Recruiting
Optimizing follow-up for interstitial lung disease
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Granollers, BarcelonaAges 18 years+ - NCT06629623Enrolling by invitation
IPF diagnosis, treatment and quality of life study
This study looks at how idiopathic pulmonary fibrosis (IPF) is diagnosed and treated, and how it affects patients' daily lives. It aims to learn from both patients and their doctors to improve care.
Beijing, Beijing MunicipalityAges Any age - NCT04016181Enrolling by invitation
Study to categorize lung fibrosis types at a clinic
This study enrolls people who have interstitial lung disease and are seen at the Edinburgh lung fibrosis clinic. It aims to sort different underlying “types” of lung fibrosis so doctors can better understand and potentially guide care.
Ages 18–99 - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Los Angeles, CaliforniaAges 40 years+ - NCT07251725Recruiting
Genetic study of family-linked lung scarring
This study looks for genetic causes of pulmonary fibrosis that runs in families. You and your affected family member(s) would provide blood samples and health info to help researchers understand why lung scarring happens.
Pavia, LombardyAges 18 years+ - NCT06482190RecruitingPhase 1
Safety study of an inhaled drug in healthy adults
This trial tests the safety of a new inhaled medicine. You must be a healthy nonsmoker, have normal lung function, and agree to avoid certain medications and foods.
Geelong, VictoriaAges 18–60 - NCT01776398Recruiting
Donating breath, blood, and urine samples for lung research
This study collects airway samples (usually during a bronchoscopy), plus blood and/or urine, to help researchers study lung conditions. It may help advance understanding of lung disease and related biology, but it is not a treatment trial.
New York, New YorkAges 18 years+ - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT05042219Recruiting
How lung disease treatment may affect heart function
This study looks at how common long-term lung conditions and their treatments may change heart function. It uses heart imaging (an MRI) to see what’s happening, which could help doctors better monitor heart risks in people with lung disease.
AachenAges 18–99 - NCT05988463RecruitingPhase 1
Study of artesunate for people with idiopathic pulmonary fibrosis
This study tests artesunate, a medicine that may help treat idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. It is for people who are already taking other IPF treatments and want to see if adding artesunate can improve their condition.
Stanford, CaliforniaAges 40 years+ - NCT07194382RecruitingPhase 2
Testing a new liquid form of nintedanib for IPF
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Camperdown, New South WalesAges 40 years+ - NCT05190211Recruiting
Video exercise therapy for idiopathic pulmonary fibrosis
This study tests whether telerehabilitation (supervised exercise/therapy by video or remote tools) can help people with idiopathic pulmonary fibrosis (IPF) improve breathing and function. You may be able to take part if your condition has been stable and you haven’t recently done a pulmonary rehab program.
Istanbul, ZeytinburnuAges 18–75 - NCT06325696RecruitingPhase 2
H01 for adults with lung scarring (SOLIS study)
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
Research Triangle Park, North CarolinaAges 18–100 - NCT03500731RecruitingPhase 1/Phase 2
Lung and bone marrow transplant for lung and blood failure
This Phase 1/2 study tests a special lung-and-bone-marrow transplant approach for people with severe lung disease and bone marrow failure (low blood counts). The goal is to see if the treatment is safe and whether it can improve outcomes when standard long-term immune-suppressing medicines are a poor fit.
Pittsburgh, PennsylvaniaAges 18–60 - NCT03800017Recruiting
Muscle strength and exercise function in lung scarring
This study looks at how well skeletal (muscle) function supports exercise in people with interstitial lung diseases (including idiopathic pulmonary fibrosis). It may help better understand fitness and breathing limits, which can guide rehabilitation choices and future care.
Vancouver, British ColumbiaAges 40–80 - NCT04442711Recruiting
Study of worsening lung symptoms in people with IPF
This study looks at people with idiopathic pulmonary fibrosis (IPF) who are currently having a sudden worsening of breathing symptoms. It may help doctors better understand what happens during these flare-ups and how to manage them.
Hellerup, CopenhagenAges 18 years+ - NCT05016817RecruitingPhase 1
Testing an IV stem cell treatment for idiopathic pulmonary fibrosis
This Phase 1 study tests whether an IV infusion of stem cells from donated umbilical cord tissue is safe for people with idiopathic pulmonary fibrosis. It focuses mainly on safety and tolerability, and it may help by offering a new treatment approach if the cells are safe for you.
St John'sAges Any age - NCT06267183RecruitingEarly Phase 1
Safety study of a new drug in healthy volunteers
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
ShanghaiAges 18–45
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idiopathic pulmonary fibrosis?
- Yes. Clin2 currently lists 86 recruiting idiopathic pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.